Back to News & Events

Bench to BARDA Start Up Series (Virtual)

The Center for Biotechnology will be co hosting a series of 6- 90 minute panel discussions with industry and government partners, focused on providing guidance and insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).

Each event will have its own specific focus, while contributing to a sequential flow for the series. Experts with specific backgrounds will provide an overview of key resources available to innovators to help fund and advance their solution from early through late stages of development, as well as provide guidance on how to navigate the funding opportunities within BARDA and BARDA DRIVe.

Session dates: June 14, 17, 21, 24, 28 and July 1st. 12:00om – 1:#0pm EST. Learn more and register: 
https://lnkd.in/gYnTAgDh

This program is a collaborative effort between incubators and accelerators who are partnered with them through their Division of Research, Innovation & Ventures (DRIVe).

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2510 [post_author] => 4 [post_date] => 2016-11-30 19:37:58 [post_date_gmt] => 2016-11-30 19:37:58 [post_content] => Codagenix, Inc. has entered into an exclusive licensing agreement with Stony Brook University, through the Research Foundation for the State of New York, to commercialize a platform technology to develop a pipeline of live attenuated vaccines against viral infections in people and animals. The technology relies on software to re-design the genomes of potentially harmful viruses to make them safe and effective vaccines. The technology stems from research in the laboratory of Eckard Wimmer, PhD, Distinguished Professor in the Department of Molecular Genetics & Microbiology. The lead indication for vaccine development generated is a vaccine against Seasonal Influenza slated for Phase I human clinical trials in 2017. Dr. Wimmer, along with Steffen Mueller, PhD, Codagenix President and Chief Science Officer, and J. Robert Coleman, PhD, Codagenix Chief Operating officer, worked as colleagues for years in Dr. Wimmer’s laboratory examining and experimenting with the genes of viruses. By collaborating with Stony Brook scientists Bruce Futcher, PhD, in the Department of Molecular Genetics & Microbiology, and Steven Skienna, PhD, in the Department of Computer Science, they discovered a way using gene manipulation and computer algorithms to “re-code” the genes of viruses. This re-coding process makes viruses extremely weak and thus ideal candidates as ultra-low dose attenuated vaccines. The licensing agreement enables Codgenix to develop and potentially market next generation vaccines using software-based gene design and whole viral synthesis to create low-dose, attenuated virus vaccines. The company expects to use this design to first test its vaccine against influenza; however, there are plans for human testing of their Zika and other vaccine candidates. Codagenix is also in partnership with a large agricultural company to make vaccines using the technology for companion and agricultural animals. The technology has been shown to be effective against numerous viruses including ZIka, Dengue, and RSV all of which are in preclinical testing. The development of this pipeline of vaccines can be seen in numerous scientific papers since 2008, including a paper in Science, PNAS, National Biotechnology and most recently in 2015 in MBIo. Read Stony Brook University's full press release here.  [post_title] => Codagenix Inks Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => codagenix-inks-exclusive-license-agreement [to_ping] => [pinged] => [post_modified] => 2017-03-15 13:49:05 [post_modified_gmt] => 2017-03-15 13:49:05 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2510 [menu_order] => 157 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3365 [post_author] => 3 [post_date] => 2019-09-20 17:23:10 [post_date_gmt] => 2019-09-20 17:23:10 [post_content] => The National Heart, Lung, and Blood Institute (NHLBI) Catalyze Program is soliciting applications for early stage translational research projects with the goal of developing basic scientific discoveries into viable therapeutics, devices, and diagnostics to treat heart, lung, blood, and sleep diseases and disorders. Funding is available for early stage technology development, including: Therapeutics (Small molecules/Biologics) - Identifying and characterizing lead compounds Devices/Diagnostics/Tools - Developing, testing, and modifying prototypes - Identifying and developing assay targets - Developing research tools Enabling Technologies and Transformative Platforms - Developing highly-innovative, next-generation technologies that could transform current approaches to clinical practice or translational research (technology must be beyond proof-of-concept and should be ready to begin validation) - Accelerating the areas of early detection and screening, animal model development, or clinical diagnosis Learn more about the program and the informational webinar taking place on October 3, 2019 on the NHLBI website. [post_title] => Funding Opportunity - NHLBI Catalyze Program [post_excerpt] => Funding is available for early stage technology development through the National Heart, Lung, and Blood Institute (NHLBI) Catalyze Program. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => funding-opportunity-nhlbi-catalyze-program [to_ping] => [pinged] => [post_modified] => 2019-09-20 17:23:10 [post_modified_gmt] => 2019-09-20 17:23:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3365 [menu_order] => 85 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2997 [post_author] => 4 [post_date] => 2018-07-02 19:00:11 [post_date_gmt] => 2018-07-02 19:00:11 [post_content] => Former Pfizer Senior Scientist and Scout Anton Xavier has joined the Center for Biotechnology in the role of Assistant Director of Technology and Business Development. Within this role at the Center, Anton will focus on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners. Anton will also provide oversight to the Center’s Commercialization Associates offering technology / business development services and education to entrepreneurial faculty and emerging companies. During his tenure at Pfizer, Anton had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications. Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs. Anton is currently a mentor and adjunct faculty member for early stage life science ventures with E-Lab NYC, ABCT (Accelerator for Biosciences in Connecticut), NSF’s I-Corps program, the British Consulate NYC, Business France, and Cornell / Columbia University, where he provides critical industry based science, strategy, and business development input for bio-venture development. Anton earned a Master’s degree in Business Administration (MBA) from Cornell University’s Johnson Graduate School of Management, a Master of Science (MSc) in Toxicology from Imperial College London and a Bachelor of Science in Biochemistry with Microbiology from Queen Mary University of London. Anton can be reached at the Center for Biotechnology by emailing anton.xavier@stonybrook.edu [post_title] => Anton Xavier Joins CFB in Technology and Business Development Role [post_excerpt] => Former Pfizer Senior Scientist and Scout will focus on the development and implementation of technology and business development strategies. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => anton-xavier-joins-cfb-in-technology-and-business-development-role [to_ping] => [pinged] => [post_modified] => 2018-07-02 19:00:40 [post_modified_gmt] => 2018-07-02 19:00:40 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2997 [menu_order] => 120 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Codagenix Inks Exclusive License Agreement

More Information

Funding Opportunity – NHLBI Catalyze Program

More Information

Anton Xavier Joins CFB in Technology and Business Development Role

More Information